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in their synthetic state produce collagen, which leads to
intimal hyperplasia.3-5 Thus, to understand the process of
phonetically modulated SMCs in the development of inti-
mal hyperplasia, the investigation of smooth muscle (SM)
phenotypes in animal models after grafting is important.
Endothelial cells (ECs) are another important compo-
nent that affects the long-term patency of a graft. Once the
intraluminal surface of the graft is covered with ECs, the
graft becomes antithrombogenic and ECs produce several
growth inhibitors for SMCs, such as prostaglandin and
nitric oxide, which results in the inhibition of the prolifera-
tion and migration of SMCs.3 For this reason, an agent that
promotes the ingrowth of ECs and inhibits proliferation
and migration of SMCs would be invaluable for the pre-
vention of intimal hyperplasia after the implantation of
prosthetic grafts. Hepatocyte growth factor (HGF) was
originally isolated from the sera of rats after partial hepate-
ctomy. The molecular weight of HGF is 82-85 kd, and it
consists of two subunits, a 69-kd -chain and a 34-kd -
chain. HGF is synthesized with fibroblasts and vascular
SMCs. The HGF receptor, C-met, is expressed on the
membrane of vascular ECs.6,7 HGF is a multipotential
cytokine that acts on ECs, stimulating migration, protease
production, proliferation, and differentiation into capillary-
like tubes in vitro. However, HGF does not promote the
proliferation and migration of vascular SMCs.8,9 Because of
The long-term results of infrainguinal arterial bypass
grafting with prosthesis of less than 6 mm in diameter have
been far from satisfactory. The major cause of the poor
results is considered to be thrombus formation in the acute
phase and obstructive intimal hyperplasia because of the
proliferation and migration of medial smooth muscle cells
(SMCs) in the anastomotic line during the chronic
phase.1,2 The proliferation and migration of vascular SMCs
play an important role in the development of the intimal
hyperplasia. A number of studies have been conducted that
are related to the suppression of the proliferation and
migration of SMCs after the interventions of arterial recon-
struction. SMCs are known to be phenotypically modu-
lated from a contractile state to a synthetic state. The SMCs
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Purpose: The major cause of vascular prosthesis failure is anastomotic intimal hyperplasia caused by the proliferation
and migration of smooth muscle cells. Hepatocyte growth factor (HGF) is an endothelium-specific growth factor that
exerts a mitogenic action on endothelial cells. This study was designed to examine the effect of HGF on the suppres-
sion of intimal hyperplasia after small-caliber expanded polytetrafluoroethylene (ePTFE) grafting.
Methods: An ePTFE graft, 2 mm in diameter and 30 mm in length, was implanted in the left common carotid arteries
of Japanese white rabbits, after which the animals were fed with a 1.0% cholesterol diet. HGF was infused intravenously
immediately and then every day for 7 days at doses of 0.3 mg/body (the 0.3-mg HGF group; n = 20) or 1.0 mg/body
(the 1.0-mg HGF group; n = 17). A control group (n = 20) underwent infusion with saline solution. The rabbits were
killed on postoperative days (PODs) 1, 2, 3, 5, 7, and 28.
Results: The patency rates on POD 28 were 33%, 55%, and 100% in the control, the 0.3-mg HGF, and the 1.0-mg HGF
groups, respectively, with a significant difference between the control and the 1.0-mg HGF group (P < .05).
Endothelial-like cells were seen on the intraluminal surface of the graft only near the anastomotic site on POD 5 in the
1.0-mg HGF group. Intimal thickness at the distal anastomosis was 284 ± 140 m, 106 ± 18 m, and 67 ± 10 m in
the control, the 0.3-mg HGF, and the 1.0-mg HGF groups, respectively, with a significant difference between the con-
trol and both HGF groups (P < .05). The number of anti–embryonic smooth muscle antibody positive cells at the dis-
tal anastomosis was 28.6 ± 0.8, 3.8 ± 2.8, and 3.9 ± 0.9 in the control, the 0.3-mg HGF, and the 1.0-mg HGF groups,
respectively, with a significant difference between the control and both HGF groups (P < .01).
Conclusion: HGF might suppress intimal thickness at the anastomotic site and improve the patency rate via rapid reen-
dothelialization by POD 28 in a rabbit carotid ePTFE grafting model. (J Vasc Surg 2002;35:786-91.)
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its unique ability to act as a mitogen for ECs, HGF shows
promising potential for the suppression of intimal hyperpla-
sia after EC injury. We hypothesized that HGF prevents
intimal hyperplasia in the anastomotic line after the implan-
tation of prosthesis in an artery. This study was performed
for the evaluation of the effect of HGF on the suppression
of anastomotic intimal hyperplasia in a cholesterol-fed rab-
bit model of carotid artery bypass grafting with expanded
polytetrafluoroethylene (ePTFE) and for the investigation
of the phenotypic modulation of SMCs and the process of
intraluminal healing in the early stage after bypass grafting.
METHODS
Animals. A total of 57 male Japanese white rabbits
that weighed 2.5 to 3.0 kg were used in this study. After
surgery, all the rabbits were fed a diet that contained 1.0%
cholesterol. SMCs in their synthetic state change into
foam cells under conditions of hyperlipidemia, and this
foam cell is a main component in the intimal hyperplasia.
So, the animals’ cholesterol feed can make the evaluation
of intimal thickness easy at the anastomosis. With the
other method, it is hard to thicken intimal hyperplasia
under normal conditions in rabbits. This experiment was
reviewed by the Committee of the Ethics on Animal
Experiment in Yamaguchi University School of Medicine
and carried out under the control of the Guideline for
Animal Experiment in Yamaguchi University School of
Medicine and The Law (No. 105) and Notification (No.
6) of the Government.
The rabbits underwent anesthesia, and the left carotid
artery was exposed in the anterior neck under sterile con-
ditions. A standard walled ePTFE graft (2 mm in diameter,
30 mm in length, and 30 m in fibril length; GORE-TEX,
W.L. Gore and Associates, Inc, Flabstaff, Ariz) was inter-
posed in an end-to-end fashion, and anastomosis was per-
formed with 12 stitches of interrupted sutures of 8-0
Fig 1. A, Intimal thickness on postoperative day 28 at both proximal and distal sites of anastomosis. Statistical difference was observed
between control and 0.3-mg hepatocyte growth factor (HGF) groups and between control and 1.0-mg HGF groups at both anasto-
motic sites. Mean ± standard error, *P < .05. B, Number of anti–embryonic smooth muscle antibody positive cells in proximal and dis-
tal graft intima on postoperative day 28. There were significant differences between control group and HGF-treated groups at both
anastomotic sites. Mean ± standard error, *P < .05, **P < .01.
B
A
polypropylene. The rabbits were divided into three exper-
imental groups. The HGF or vehicle was infused immedi-
ately after surgery through the ear vein and then every day
for 7 days after surgery. A control group of 20 rabbits was
given 1.0 mL of saline solution intravenously as a vehicle.
The remaining rabbits were divided into two groups. One
group (n = 20 rabbits) underwent treatment with an intra-
venous injection of 0.3 mg/body HGF (0.3-mg HGF
group), and another group (n = 17 rabbits) underwent
treatment with 1.0 mg/body HGF in the same manner
(1.0-mg HGF group). The dosages and prescribed periods
were arbitrarily selected in part on the basis of previous
evidence that 0.05 to 0.25 mg/kg HGF administered as a
daily intravenous bolus injection five times between 6 days
prevents acute renal failure after HgCl2 administration.10
This study used recombinant human HGF, which was
purified from a culture medium of CHO cells transfected
with an expression vector that contained deletion-type
human HGF complementary DNA, and the purity of
HGF exceeded 98%. The rabbits were killed on postoper-
ative days (PODs) 1, 2, 3, 5, 7, and 28. After the rabbits
had been anesthetized, the ePTFE graft was exposed and
the graft patency was checked with Doppler scan signals.
The ePTFE graft and the host artery were fixed antegrade,
first in 500 mL of 0.9% saline solution and then in 500 mL
of 4% paraformaldehyde at a pressure of 120 mm Hg, after
which the ePTFE grafts were harvested.
Evaluation of intimal thickness and smooth muscle
phenotype. The removed samples were embedded in
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paraffin, cut along the longitudinal axis, and stained with
hematoxylin-eosin. The intimal thickness was measured
with a computerized sketching program (Mac Scope, ver-
sion 2.55, Mitani Corporation, Tokyo, Japan) at the fol-
lowing three positions: the anastomotic line and 100 m
and 200 m away from the anastomotic line. These three
numeric values were averaged and used as a representative
value. For immunohistochemical analysis, monoclonal
antibodies against human SM2 (Yamasa, Japan) and
embryonic SM (SMemb; Yamasa, Japan) were used for
staining myosin heavy chain isoforms in SMCs. Vascular
SMCs contain the following two types of SM myosin
heavy chain: SM1 and SM2, the isoforms of which are spe-
cific markers for SMC differentiation. SM2 is particularly
useful as a marker of contractile-state SMCs. On the other
hand, SMemb is known as a nonmuscle myosin heavy
chain and is isolated from both the fetal aorta and the
brain. SMemb is predominantly expressed in undifferenti-
ated vascular SMCs and is reduced during vascular devel-
opment.4,11 SMemb is especially important for the
investigation of the synthetic-state SMCs. Therefore, we
measured the number of anti-SMemb antibody positive
cells in the intima on POD 28. The number of anti-
SMemb antibody positive cells was counted with the same
computer program. We also assessed the anti-SM2 anti-
body positive area on POD 28.
Data analysis. The patency rate was evaluated with
the Fisher exact test. The differences between means were
assessed with the Bartlett test and were evaluated with the
Fig 2. Light microscopic findings at distal anastomosis on postoperative day (POD) 5 and POD 7 in hepatocyte growth factor
(HGF)–treated group. Endothelial-like cells were seen on POD 5 in 1.0-mg HGF group and on POD 7 in 0.3-mg HGF group (hema-
toxylin-eosin stain, 20). A, POD 5 in 0.3-mg HGF group; B, POD 7 in 0.3-mg HGF group; C, POD 5 in 1.0-mg HGF group; D,
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Scheffé test. Values are expressed as means ± standard
error. A P value of less than .05 was considered statistically
significant. 
RESULTS
Patency rates and intimal thickness. The patency
rate on POD 7 was 100% in all the groups. However, by
POD 28, the patency rates were 33% (three of nine cases)
in the control group, 55% (five of nine cases) in the 0.3-
mg HGF group, and 100% (seven of seven cases) in the
1.0-mg HGF group. There was a statistically significant
difference between the control group and the 1.0-mg
HGF group (P < .05). The intimal thickness at both anas-
tomotic sites on POD 28 is shown in Fig 1,A. Intimal
thickness at the proximal and distal anastomosis was 201 ±
90 m and 286 ± 140 m, respectively, in the control
group, 61 ± 5 m and 106 ± 18 m, respectively, in the
0.3-mg HGF group, and 66 ± 7 m and 67 ± 10 m,
respectively, in the 1.0-mg HGF group. There was a sta-
tistical difference between the control and the 0.3-mg
HGF groups and between the control and the 1.0-mg
HGF groups at both anastomotic sites (P < .05).
Microscopic findings. Fig 2 shows the microscopic
findings in the HGF-treated group. Fibrin net was seen in
the ePTFE graft near the anastomotic site in all the groups
on POD 1 and propagated to the mid-portion of the
ePTFE graft on POD 5. On the other hand, endothelial-
like cells were seen only near the anastomotic site on POD
5 in the 1.0-mg HGF group and on POD 7 in the 0.3-mg
HGF group (Fig 2), but were not seen in the mid-portion
of the graft. The monolayer of endothelial-like cells of
graft luminal surface looked like reendothelialization in
the 1.0-mg HGF group on POD 7 (Fig 3,A), whereas no
endothelial-like cells were observed in the control group
within 7 days. On POD 28, the intraluminal surface of the
graft only near the anastomotic site in all the groups was
covered with endothelial-like cells but did not show
endothelial-like cells in the mid-portion of the graft (data
not shown). These are endothelial-like cells, but the vari-
ous methods for the identification of endothelium in other
species were tried without success in this rabbit model.
Accumulation of smooth muscle cells. On POD 5,
anti-SMemb antibody positive cells were seen just beneath
the EC layer of the host artery in all the groups (Fig 3,B).
On POD 28, there were a number of anti-SMemb antibody
positive cells in the intimal hyperplasic area in the control
group. However, in the HGF-treated groups, the number of
anti-SMemb antibody positive cells was not as prominent as
that seen in the control group (Fig 4). The number of anti-
SMemb antibody positive cells in the intima of the proximal
site on POD 28 was 20.3 ± 3.8 in the control group, 3.3 ±
1.5 in the 0.3-mg HGF group, and 6.2 ± 0.8 in the 1.0-mg
HGF group. There were significant differences between the
control group and the HGF-treated groups (P < .05; Fig
1,B). The number of anti-SMemb antibody positive cells in
the intima of the distal site was 28.6 ± 0.8 in the control
group, 3.8 ± 2.8 in the 0.3-mg HGF group, and 3.9 ± 0.9
in the 1.0-mg HGF group. The number of anti-SMemb
antibody positive cells at the distal anastomosis was signifi-
cantly less in the HGF-treated groups than in the control
group (P < .01; Fig 1,B). Evaluation results of the anti-SM2
antibody on POD 28 revealed that there was an anti-SM2
antibody positive area in the media of the host artery but not
in the graft intima of any groups (data not shown).
DISCUSSION
The results of this study showed that HGF signifi-
cantly reduced the development of intimal hyperplasia in
cholesterol-fed rabbits after carotid ePTFE grafting.
Anastomotic intimal thickness is the most common cause
of late graft failure after peripheral arterial reconstruction.
A hypothesis has been proposed that after the implanta-
tion of prosthetic graft, vascular endothelial injuries near
Fig 3. A, Monolayer of endothelial-like cells on graft luminal sur-
face (black arrow) looked like reendothelialization in 1.0-mg
hepatocyte growth factor group on postoperative day 7 (hema-
toxylin-eosin stain, 40). B, Expression of anti–embryonic smooth
muscle antibody positive cells in media of distal site in 1.0-mg
hepatocyte growth factor group on postoperative day 5.
Anti–embryonic smooth muscle antibody positive cells, which
were stained brown (black arrow), were seen below endothelial
cells (white arrow), which indicates beginning of migration of syn-
thetic state smooth muscle cells. 
A
B
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the anastomotic line and the subsequent exposure of
subendothelial tissue to plasma constituents cause intimal
thickness. In the initial stage of intimal thickness, endothe-
lium near the denuded subendothelial tissue induce the
migration and proliferation of SMCs and in the media of
the adjacent vessel migrate into the intima.2,12 After that,
SMCs migrate to the synthetic graft, and the synthesis of
connective tissue proteins, under the influence of various
mitogenic factors, are now considered to be major
processes involved in the formation of intimal thickness.
And moreover, once the SMCs are covered with an intact
endothelial monolayer, SMC proliferation returns to the
base line, except at the anastomotic site.13
In the proliferative intimal thickness response, the syn-
thetic phenotype of SMCs plays a major role. The pheno-
typic modulation of SMCs from the contractile state to the
synthetic state was first described by Chamley-Campbell,
Campbell, and Ross,5 and electron microscopic study
results have revealed that SMCs in their synthetic state in
culture lose much myofilament and are abundant in subcel-
lular organelles involved in protein synthesis. In fact, SMCs
in their synthetic state promote the proliferation, migration,
and production of connective tissue and change into foam
cells during the chronic phase under conditions of hyper-
lipidemia.14 The synthetic state of SMCs is stimulated with
proliferative factors, such as platelet-derived growth factor,
fibroblast growth factor (FGF), and transforming growth
factor–, which are released from platelets, macrophages,
and ECs for paracrine and from SMCs for autocrine.3 Once
phenotypic modulation occurs, the synthetic state of SMCs
keep proliferating and migrating for at least 3 months.15
However, the proliferation of SMCs has been found to be
suppressed with antiproliferative factors, such as nitric
oxide, prostaglandin, and C-type natriuretic peptide
released from ECs, and reendothelialization occurs after 3
to 4 weeks.16,17 Therefore, earlier promotion and facilita-
tion of the proliferation of ECs would control the prolifer-
ation and migration of SMCs in the acute phase, thereby
preventing intimal hyperplasia in the chronic phase.
HGF, vascular endothelial growth factor, and bFGF
are known to strongly stimulate the proliferation of ECs.
The effect of HGF on ECs is 1.48 times stronger than that
of bFGF, whereas that of vascular endothelial growth fac-
tor is 1.25 times stronger. Furthermore, bFGF stimulates
the proliferation and migration of SMCs, which may cause
intimal hyperplasia at the anastomotic site. However, HGF
does not promote the proliferation and migration of
SMCs.15,18 With the consideration of these facts, HGF
seems to be the most ideal growth factor for the preven-
tion of intimal hyperplasia.
In this systemic prescribed study, our microscopic
findings showed that endothelial-like cells started to cover
the intraluminal surface of the ePTFE graft only at the
anastomotic site on POD 5 in the 1.0-mg HGF group,
which suggests that endothelial-like cells migrated from
the host artery. Earlier reendothelialization was seen in the
1.0-mg HGF group sooner than in the 0.3-mg HGF
group, which indicates that the effect of reendothelializa-
Fig 4. Expression of anti–embryonic smooth muscle (SMemb)
antibody positive cells in intima of distal site on postoperative day
28. A number of anti-SMemb antibody positive cells were seen in
intimal hyperplasic area in control group. However, in hepatocyte
growth factor (HGF)–treated groups, number of anti-SMemb
antibody positive cells was not as prominent as in control group.





JOURNAL OF VASCULAR SURGERY
Volume 35, Number 4 Harada et al 791
tion with systemic prescribed HGF graft might be dose-
dependent. This rapid regeneration of endothelial-like
cells associated with the HGF treatment suggests that it is
effective in the suppression of intimal hyperplasia. The
HGF-treated groups showed less intimal thickening than
did the control group on POD 28, and the fact that the
number of anti-SMemb antibody positive cells were sig-
nificantly less in the HGF group than in the control group
supports the belief that the proliferation and migration of
SMCs is inhibited with the rapid regrowth of endothelial-
like cells. Thus, systemic prescribed HGF was clearly effec-
tive in this implantation model.
The half-life of the HGF concentration in rats has
been reported as 3.8 minutes,19 60% of which is metabo-
lized in the liver. Therefore, if HGF were administered as
a bolus injection, a high dose would be necessary. The
process of the synthetic state of SMCs was evaluated with
a histochemical stain with the anti-SMemb antibody. On
POD 1, anti-SMemb antibody positive cells were seen in
the media of host arteries in all the groups (data not
shown), which suggests that the phenotypic modulation
of SMCs was begun within 24 hours. Anti-SMemb anti-
body positive cells were seen in all the groups within 7
days, and by POD 28, the number of anti-SMemb anti-
body positive cells in the anastomotic intima was signifi-
cantly less in the HGF groups than in the control groups.
However, anti-SM2 antibody positive area was seen in the
media of the host artery on POD 28 but not in the areas
of intimal hyperplasia in all the groups. With the consider-
ation of these facts, HGF may act as a suppressor of the
proliferation and migration of SMCs, probably through
rapid reendothelialization, but not as a promoter of the
redifferentiation of SMCs.
The migration of SMCs in their synthetic state started
below the monolayer of ECs on POD 5 in this model. In
a rabbit balloon injury model, Davies and Hagen2
reported that by 5 days after injury, SMCs were observed
on the luminal side of the internal elastic lamina, which
appeared to have migrated to the luminal surface through
fenestrations in the internal elastic lamina. Casscells20
reported that by 5 days after injury, SMCs had migrated
into the neointima in the same model. These results indi-
cate that the regeneration of ECs should be completed
within 5 days after surgery to suppress the proliferation
and migration of SMCs in both the balloon injury model
and the grafting model. HGF was administered immedi-
ately after surgery and then every day for 7 days after
surgery in our model. The early stage of HGF treatment
was considered to be the key point for the improvement of
the patency rate and for the reduction of anastomotic inti-
mal hyperplasia in this study.
CONCLUSION
The results of this study clearly showed that HGF
treatment significantly reduced intimal thickness in both
the proximal and the distal anastomosis after carotid
ePTFE grafting in cholesterol-fed rabbits. HGF treatment
was also considered to stimulate endothelial ingrowth on
the ePTFE graft. These effects may be attributable to the
indirect inhibition of the migration and proliferation of
SMCs via rapid reendothelialization at the anastomotic
site. Thus, the significant inhibition of intimal thickness
with HGF may contribute to improved long-term patency
after arterial grafting.
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